Latest On Lineage Cell Therapeutics, Inc (LCTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 11:15 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 21:39 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $2.39M beats by $0.38M | N/A | |
| 2023-03-10 10:10 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-09 18:48 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.15 in-line, revenue of $14.7M misses by $0.63M | N/A | |
| 2023-03-09 03:24 EST | News | Lineage Cell Therapeutics Q4 2022 Earnings Preview | N/A | |
About Lineage Cell Therapeutics, Inc (LCTX):
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical read more...trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
General
- Name Lineage Cell Therapeutics, Inc
- Symbol LCTX
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 49
- Last Split Factor3:1
- Last Split Date1997-10-31
- Fiscal Year EndDecember
- IPO Date1992-03-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.lineagecell.com
Valuation
- Trailing PE 3.63
- Price/Sales (Trailing 12 Mt.) 127.09
- Price/Book (Most Recent Quarter) 3.78
- Enterprise Value Revenue 114.22
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.16
- Next Year EPS Estimate -$0.21
- Next Quarter EPS Estimate -$0.04
- Operating Margin -1410%
- Return on Assets -14%
- Return on Equity -20%
- Revenue 1.83 million
- Earnings Per Share $0.23
- Revenue Per Share $0.01
- Gross Profit 1.44 million
- Quarterly Earnings Growth -71.4%
Highlights
- Market Capitalization 412.18 million
- EBITDA -36699000
- PE Ratio -6.9
- Analyst Target Price $5.2
- Book Value Per Share $0.78
Share Statistics
- Shares Outstanding 161.64 million
- Shares Float 120.46 million
- % Held by Insiders 505%
- % Held by Institutions 35.77%
- Shares Short 3.85 million
- Shares Short Prior Month 4.6 million
- Short Ratio 2.01
- Short % of Float 3%
- Short % of Shares Outstanding 3%
Technicals
- Beta 1.93
- 52 Week High $3.13
- 52 Week Low $0.65
- 50 Day Moving Average 2.48
- 200 Day Moving Average 1.7
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Lineage Cell Therapeutics, Inc (LCTX) Dividend Calendar:
Lineage Cell Therapeutics, Inc (LCTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Lineage Cell Therapeutics, Inc (LCTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Lineage Cell Therapeutics, Inc (LCTX) Chart:
Lineage Cell Therapeutics, Inc (LCTX) News:
Below you will find a list of latest news for Lineage Cell Therapeutics, Inc (LCTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Lineage Cell Therapeutics, Inc (LCTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest LCTX Trades:
Lineage Cell Therapeutics, Inc (LCTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 8-K (Current report) | |
| 2020-11-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-09-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-23 | 8-K (Current report) | |
| 2020-09-14 | 8-K (Current report) | |
| 2020-08-10 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-08-10 | DEF 14A (Other definitive proxy statements) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-21 | 8-K (Current report) | |
| 2020-05-08 | EFFECT (Notice of Effectiveness) | |
Lineage Cell Therapeutics, Inc (LCTX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Lineage Cell Therapeutics, Inc (LCTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 505%
Institutional Ownership: 3577%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | Brian M Culley | President and CEO | Buy | 15,450.00 | 0.94 | 14,470.47 | 180,838.00 | |
| 2020-06-30 | Brian M Culley | President and CEO | Buy | 15,450.00 | 0.87 | 13,441.50 | 170,731.00 | |
| 2020-03-31 | Brian M Culley | President and CEO | Buy | 15,450.00 | 0.83 | 12,794.15 | 160,624.00 | |
| 2020-01-02 | Lineage Cell Therapeutics, Inc. | Insider | Sell | 2,383,090.00 | 2.16 | 5,137,942.04 | 6,041,154.00 | |
| 2019-12-31 | Brian M Culley | President and CEO | Buy | 15,450.00 | 150,517.00 | | ||
| 2019-09-30 | Brian M Culley | President and CEO | Buy | 15,450.00 | 140,410.00 | | ||
| 2019-09-17 | Brian M Culley | President and CEO | Buy | 61,800.00 | 146,331.00 | | ||
| 2019-09-11 | Lineage Cell Therapeutics, Inc. | 10% Share Holder | Sell | 4,000,000.00 | 1.66 | 6,640,000.00 | 8,424,244.00 | |
| 2019-08-15 | BROADWOOD PARTNERS, L.P. | Director | Buy | 0.00 | 34,005,379.00 | | ||
| 2019-08-15 | BROADWOOD PARTNERS, L.P. | Director | Buy | 13,146.00 | 0.97 | 12,717.44 | 34,005,379.00 | |
| 2019-08-14 | BROADWOOD PARTNERS, L.P. | Director | Buy | 0.00 | 33,992,233.00 | | ||
| 2019-08-14 | BROADWOOD PARTNERS, L.P. | Director | Buy | 1,407.00 | 0.98 | 1,378.86 | 33,992,233.00 | |
| 2019-08-13 | BROADWOOD PARTNERS, L.P. | Director | Buy | 0.00 | 33,990,826.00 | | ||
| 2019-08-13 | BROADWOOD PARTNERS, L.P. | Director | Buy | 10,000.00 | 0.99 | 9,949.00 | 33,990,826.00 | |
| 2019-08-13 | Brandi Roberts | CFO & SVP, Finance | Buy | 5,000.00 | 1.01 | 5,050.00 | 5,000.00 | |
| 2019-08-13 | Chase C. Leavitt | General Counsel/Secretary | Buy | 5,000.00 | 1.02 | 5,100.00 | 5,000.00 | |
| 2019-08-13 | Brian M Culley | President and CEO | Buy | 10,000.00 | 1.01 | 10,100.00 | 84,531.00 | |
| 2019-07-05 | BIOTIME INC | 10% Share Holder | Sell | 2,250,000.00 | 2.00 | 4,500,000.00 | 12,424,244.00 | |
| 2019-03-08 | Michael H. Mulroy | Director | Buy | 194,271.00 | 226,821.00 | | ||
| 2019-03-08 | ALFRED D KINGSLEY | Director | Buy | 6,390.00 | 5,457,945.00 | |